# Virologic and immunologic impacts of active viral persistence in lung AMs of HIV-1-infected, cART-suppressed individuals

> **NIH AI R01** · STATE UNIVERSITY OF NEW YORK AT BUFFALO · 2026 · $152,468

## Abstract

Project Summary / Abstract
 Persistence of HIV-1 in tissue reservoirs of therapy-suppressed, aviremic individuals is a major challenge
to HIV-1 cure. The viral reservoir consists of myeloid and lymphoid cells that harbor the virus through long periods
of combination anti-retroviral therapy (cART). Until recently, it was thought that HIV-1 provirus remains in a
transcriptionally-silent, latent state in these reservoir cells and only resumes viral transcription and virion
production upon activation from endogenous or exogenous stimuli. However, it is now evident that in a subset
of reservoir cells, the virus remains transcriptionally-active even under cART and continues to generate some
levels of viral RNAs and/or proteins. Even in absence of complete viral replication, persistent viral RNA and
protein production in these “active” reservoirs pose significant adverse immunologic and virologic consequences.
They can contribute to the chronic immune activation as well as impact viral rebound upon treatment interruption.
Along with the transcriptionally-silent, latently-infected cells, elimination of these viral transcriptionally-active
reservoirs would be necessary to achieve a cure for HIV-1.
 Most of our current knowledge of active HIV-1 reservoirs is limited to studies of CD4+ T-cells in the
peripheral blood. The nature of active reservoirs in myeloid cells within tissue compartments have remained
largely uncharacterized. In our preliminary studies, we have shown that alveolar macrophages (AMs), which are
the predominant HIV-1-infected cell-type in the lung, continue to transcribe viral RNAs under long-term cART.
We have also shown that, unlike CD4+ T-cells, the levels of viral RNA-positive AMs do not decrease even after
years-long therapy. In this study, we propose to comprehensively characterize these active AM reservoirs in
therapy-suppressed individuals by addressing three specific questions: (1) how the proviral landscapes and
profiles of viral RNA transcripts in

## Key facts

- **NIH application ID:** 11518107
- **Project number:** 3R01AI176934-03S1
- **Recipient organization:** STATE UNIVERSITY OF NEW YORK AT BUFFALO
- **Principal Investigator:** Saikat  Boliar
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** AI
- **Fiscal year:** 2026
- **Award amount:** $152,468
- **Award type:** 3
- **Project period:** 2024-05-17T00:00:00 → 2029-03-31T00:00:00

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/11518107

## Citation

> US National Institutes of Health, RePORTER application 11518107, Virologic and immunologic impacts of active viral persistence in lung AMs of HIV-1-infected, cART-suppressed individuals (3R01AI176934-03S1). Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/grant/nih/11518107. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*